Coronavirus Disease 2019 Clinical Trial
Official title:
A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate Coronavirus Disease 2019 (COVID-19)
This is a Phase 2, two-arm, randomized, double blind, placebo controlled multicenter study to evaluate the safety and efficacy of leronlimab (PRO 140) in patients with mild-to-moderate symptoms of respiratory illness caused by coronavirus 2019 infection.
This is a Phase 2, two-arm, randomized, double blind, placebo controlled multicenter study to evaluate the safety and efficacy of leronlimab (PRO 140) in patients with mild-to-moderate symptoms of respiratory illness caused by coronavirus 2019 infection. Patients will be randomized to receive weekly doses of 700 mg leronlimab (PRO 140), or placebo. Leronlimab (PRO 140) and placebo will be administered via subcutaneous injection. The study will have three phases: Screening Period, Treatment Period, and Follow-Up Period. A total of 75 subjects will be randomized 2:1 in this study. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05091411 -
Clinical Trials of the Consistency and Non-inferiority Bridging Between Batches of Recombinant New Coronavirus Vaccine (CHO Cells)
|
Phase 3 | |
| Completed |
NCT05107375 -
Clinical Study of Recombinant Novel Coronavirus（COVID-19） Vaccine (CHO Cell) Combined With Influenza Vaccine
|
Phase 3 | |
| Active, not recruiting |
NCT05128643 -
Clinical Study on the Immune Program of Recombinant Novel Coronavirus（COVID-19) Vaccine (CHO Cell)
|
Phase 3 | |
| Completed |
NCT04988217 -
Inhaled Interferon α2b for the Treatment of Coronavirus Disease 19 (COVID-19)
|
Phase 1/Phase 2 | |
| Completed |
NCT04579393 -
Fostamatinib for Hospitalized Adults With COVID-19
|
Phase 2 | |
| Withdrawn |
NCT04390217 -
LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia
|
Phase 2 | |
| Recruiting |
NCT05047783 -
Masitinib in Patients With Symptomatic Mild to Moderate COVID-19
|
Phase 2 | |
| Completed |
NCT04646044 -
A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19
|
Phase 1 | |
| Not yet recruiting |
NCT06392451 -
LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia
|
N/A | |
| Recruiting |
NCT05092568 -
Comparison of General Characteristics of Patients Diagnosed COVID-19 (Coronavirus )Positive Followed In Service
|
||
| Completed |
NCT05364268 -
Evaluation of the AudibleHealth Dx AI/ML-Based Dx SaMD Using FCV-SDS in the Diagnosis of COVID-19 Illness: Clinical Validation
|
||
| Completed |
NCT06189040 -
Immunogenicity After COVID-19 Vaccines in Adapted Schedules
|
Phase 4 | |
| Recruiting |
NCT04401436 -
COVID-19 Associated Lymphopenia Pathogenesis Study in Blood
|
||
| Not yet recruiting |
NCT04395742 -
1,3,7-Trimethylxanthine as a Treatment of COVID-19: Results of a Controlled Study
|
||
| Recruiting |
NCT04388631 -
Detection Rate of SARS-CoV-2 in Male Genitourinary System and Its Impact on Male Reproductive Health.
|
||
| Completed |
NCT05501288 -
Huashi Baidu Granule in the Treatment of Pediatric Patients With Mild Coronavirus Disease 2019
|
N/A | |
| Active, not recruiting |
NCT05216471 -
Identify Coronavirus Disease by Chest X-ray
|
||
| Terminated |
NCT04672564 -
Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients
|
Phase 3 | |
| Completed |
NCT04967781 -
Autoimmunity Contributes to the Severe Progression of COVID-19
|
||
| Completed |
NCT04678830 -
Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19
|
Phase 2 |